title: CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy.
abstract: The high levels of preexisting immunity against Adenovirus type 5 (Ad5) have deemed Ad5 unusable for translation as a human vaccine vector. Low seroprevalent alternative viral vectors may be less impacted by preexisting immunity, but they may also have significantly different phenotypes from that of Ad5. In this study we compare species D Ads (26, 28, and 48) to the species C Ad5. In vitro transduction studies show striking differences between the species C and D viruses. Most notably, Ad26 transduced human dendritic cells much more effectively than Ad5. In vivo imaging studies showed strikingly different transgene expression profiles. The Ad5 virus was superior to the species D viruses in BALB/c mice when delivered intramuscularly. However, the inverse was true when the viruses were delivered mucosally via the intranasal epithelia. Intramuscular transduction was restored in mice that ubiquitously expressed human CD46, the primary receptor for species D viruses. We analyzed both species C and D Ads for their ability to induce prophylactic immunity against influenza in the CD46 transgenic mouse model. Surprisingly, the species D vaccines again failed to induce greater levels of protective immunity as compared with the species C Ad5 when delivered intramuscularly. However, the species D Ad vaccine vector, Ad48, induced significantly greater protection as compared with Ad5 when delivered mucosally via the intranasal route in CD46 transgenic mice. These data shed light on the complexities between the species and types of Ad. Our findings indicate that more research will be required to identify the mechanisms that play a key role in the induction of protective immunity induced by species D Ad vaccines.
authors.affiliation: 1 Cell Biology, Department of Natural Sciences, Western New Mexico University , Silver City, NM 88062.
authors.forename: Zenaido T
authors.initials: ZT
authors.lastname: Camacho
authors.forename: Mallory A
authors.initials: MA
authors.lastname: Turner
authors.forename: Michael A
authors.initials: MA
authors.lastname: Barry
authors.forename: Eric A
authors.initials: EA
authors.lastname: Weaver
mesh_terms: D000256:Adenoviridae / Q000145:classification / Q000235:genetics / Q000276:immunology*; D062705:Adenovirus Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D000818:Animals; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007273:Injections, Intramuscular; D051916:Membrane Cofactor Protein / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008822:Mice, Transgenic; D009092:Mucous Membrane / Q000276:immunology* / Q000378:metabolism*; D009297:Nasal Mucosa / Q000276:immunology / Q000378:metabolism; D014161:Transduction, Genetic
chemical_list: D062705:Adenovirus Vaccines; D051916:Membrane Cofactor Protein